We serve Chemical Name:3-Amino-1H-indazol-6-ol CAS:88805-72-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Amino-1H-indazol-6-ol
CAS.NO:88805-72-5
Synonyms:3-Amino-1H-indazol-6-ol;3-Amino-6-hydroxy-1H-indazole;1H-Indazol-6-ol, 3-amino-;1H-Indazol-6-ol,3-amino
Molecular Formula:C7H7N3O
Molecular Weight:149.150
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:476.4±25.0 °C at 760 mmHg
Density:1.6±0.1 g/cm3
Index of Refraction:1.848
PSA:74.93000
Exact Mass:149.058914
LogP:0.47
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Amino-1H-indazol-6-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indazol-6-ol,3-amino physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Indazol-6-ol, 3-amino- Use and application,1H-Indazol-6-ol,3-amino technical grade,usp/ep/jp grade.
Related News: In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said. 3-Amino-1H-indazol-6-ol manufacturer Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more. 3-Amino-1H-indazol-6-ol supplier APIs are generally manufactured through a variety of processes that include. 3-Amino-1H-indazol-6-ol vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 3-Amino-1H-indazol-6-ol factory Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.
